Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

Delia Bishara1, David Taylor1,21Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK; 2Division of Pharmaceutical Sciences, King’s College, London, UKAbstract: Asenapine is a new atypical antipsychotic agent currently under development for the t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Delia Bishara, David Taylor
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/a505025bb6854ca5b5e8c41bb5f7597a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a505025bb6854ca5b5e8c41bb5f7597a
record_format dspace
spelling oai:doaj.org-article:a505025bb6854ca5b5e8c41bb5f7597a2021-12-02T07:53:12ZAsenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder1176-63281178-2021https://doaj.org/article/a505025bb6854ca5b5e8c41bb5f7597a2009-09-01T00:00:00Zhttp://www.dovepress.com/asenapine-monotherapy-in-the-acute-treatment-of-both-schizophrenia-and-a3562https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Delia Bishara1, David Taylor1,21Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK; 2Division of Pharmaceutical Sciences, King’s College, London, UKAbstract: Asenapine is a new atypical antipsychotic agent currently under development for the treatment of schizophrenia and bipolar disorder. It has high affinity for various receptors including antagonism at 5HT2A, 5HT2B, 5HT2C, 5HT6 and 5HT7 serotonergic receptor subtypes, α1A, α2A, α2B and α2C adrenergic and D3 and D4 dopaminergic receptors. As with other atypicals, asenapine exhibits a high 5HT2A:D2 affinity ratio. Although similar to clozapine in its multitarget profile, it shows no appreciable affinity for muscarinic receptors. Asenapine has shown efficacy in alleviating both positive and negative symptoms of schizophrenia compared with placebo. Although promising, further studies are required in order to determine whether it has advantages over placebo and other antipsychotics in alleviating cognitive impairment associated with schizophrenia. It has also shown long-term efficacy comparable with olanzapine in bipolar I disorder. Asenapine is generally well tolerated and appears to be metabolically neutral. It has low propensity to cause weight gain and prolactin elevation. There were no concerns in the studies about its effects on the cardiovascular system and QTc prolongation. The incidence of extrapyramidal symptoms with asenapine however has been found to be higher than that with olanzapine. It may be a useful alternative to aripiprazole in schizophrenia and bipolar disorder in patients who are at high risk of metabolic abnormalities.Keywords: asenapine, schizophrenia, bipolar I disorder, antipsychotics Delia BisharaDavid TaylorDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 483-490 (2009)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Delia Bishara
David Taylor
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
description Delia Bishara1, David Taylor1,21Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK; 2Division of Pharmaceutical Sciences, King’s College, London, UKAbstract: Asenapine is a new atypical antipsychotic agent currently under development for the treatment of schizophrenia and bipolar disorder. It has high affinity for various receptors including antagonism at 5HT2A, 5HT2B, 5HT2C, 5HT6 and 5HT7 serotonergic receptor subtypes, α1A, α2A, α2B and α2C adrenergic and D3 and D4 dopaminergic receptors. As with other atypicals, asenapine exhibits a high 5HT2A:D2 affinity ratio. Although similar to clozapine in its multitarget profile, it shows no appreciable affinity for muscarinic receptors. Asenapine has shown efficacy in alleviating both positive and negative symptoms of schizophrenia compared with placebo. Although promising, further studies are required in order to determine whether it has advantages over placebo and other antipsychotics in alleviating cognitive impairment associated with schizophrenia. It has also shown long-term efficacy comparable with olanzapine in bipolar I disorder. Asenapine is generally well tolerated and appears to be metabolically neutral. It has low propensity to cause weight gain and prolactin elevation. There were no concerns in the studies about its effects on the cardiovascular system and QTc prolongation. The incidence of extrapyramidal symptoms with asenapine however has been found to be higher than that with olanzapine. It may be a useful alternative to aripiprazole in schizophrenia and bipolar disorder in patients who are at high risk of metabolic abnormalities.Keywords: asenapine, schizophrenia, bipolar I disorder, antipsychotics
format article
author Delia Bishara
David Taylor
author_facet Delia Bishara
David Taylor
author_sort Delia Bishara
title Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
title_short Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
title_full Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
title_fullStr Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
title_full_unstemmed Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
title_sort asenapine monotherapy in the acute treatment of both schizophrenia and bipolar i disorder
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/a505025bb6854ca5b5e8c41bb5f7597a
work_keys_str_mv AT deliabishara asenapinemonotherapyintheacutetreatmentofbothschizophreniaandbipolarampnbspidisorder
AT davidtaylor asenapinemonotherapyintheacutetreatmentofbothschizophreniaandbipolarampnbspidisorder
_version_ 1718399117623820288

Ejemplares similares